Ask our AI-chatbot
Planned

Cell and Gene Therapy for Personalised Medicine

Published 14 Oct 2026

Published 14 Oct 2026
Download
Financial schemeJoint transnational calls
ProgramEuropean partnership for personalised medicine (EP PerMed)
Date call is made active4 November 2026
Preproposal20 January 2027, 14:00 CET
Full proposal25 May 2027, 14:00 CEST
Relevant thematic areas for this callGround-breaking research, Health, Life science
Target groupsPublic sector, Industry, Research organisations
Contact
Send us your question
The call aims to encourage and enable interdisciplinary and cross-sectorial research collaborations on on the development and validation of an innovative and novel cell and gene therapy for personalized medicine. 

The proposals must focus on the development and validation of an innovative and novel cell and gene therapy for personalized medicine. At least one of the following approaches must be employed:

  • Somatic cell therapeutics
  • Gene therapeutics
  • Combined cell- and gene therapeutics
  • Novel biological products such as mRNA, other nucleic acid-based methods, and extracellular vesicles as vehicle for gene-based therapeutic procedure.

SME or other industrial partner is funded with up to 50% of their eligible project costs (see details in the State Aid rules, Article 25). All applicants and partners must comply with the State Aid rules. All projects are to be carried out as effective collaboration between the partners. Undertakings (companies) that participate in the consortium must also not receive indirect state aid in the form of advantageous conditions for cooperation with the research institutions taking part in the consortium. Conditions for awarding state aid.

Website: https://www.eppermed.eu/funding-projects/calls/jtc2027/

Messages at time of print 14 October 2026, 14:28 CEST

No global messages displayed at time of print.